• Pure Extracts (PULL) starts the initial production run of 50,000 gummy packs for provincial distribution
  • Revenue estimates associated with this batch are approximately $200,000
  • For this launch, Pure plans to include 3 SKUs with varying levels of ultra-high potency CBD Pure Chews non-THC gummies
  • Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of Whistler, British Columbia
  • Pure Extracts Technologies Corp. (PULL) is down 7.14 per ent and is trading at C$0.39 at 11:31 am ET

Pure Extracts Technologies Corp. (PULL) has begun production on approximately 50,000 Pure Chews edible gummy packs.

Demand for these types of products is strong in the four provinces (British Columbia, Alberta, Saskatchewan and Ontario) that Pure is targeting for its retail launch and revenue estimates associated with this batch are approximately $200,000.

All the Pure Chews SKUs including the 10 mg THC packs of Fire Burst, Strawberry and Mango utilize a proprietary manufacturing system licensed from US-based Taste-T, LLC, the manufacturer of Margarita Chill and Fireball Cinnamon products, to produce and package branded cannabis gummies that come in unique blister packaging.

For this launch, Pure plans to include 3 SKUs with varying levels of ultra-high potency CBD Pure Chews non-THC gummies.

Pure Extracts CEO, Ben Nikolaevsky, remarked,

“May is going to be a very exciting month for us as we commence retail sales of gummies through our distribution partner.”

“Our exceptionally pure products are in high demand and we have a range in potencies and flavours that consumers will certainly enjoy,” added Nikolaevsky.

Pure Extracts features an all-new, state-of-the-art processing facility located just 20 minutes north of Whistler, British Columbia.

Pure Extracts Technologies Corp. (PULL) is down 7.14 per ent and is trading at C$0.39 at 11:31 am ET.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.